Authors ’ Reply to Yusuf Ziya Sener: “Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study”
(Source: Targeted Oncology)
Source: Targeted Oncology - May 27, 2020 Category: Cancer & Oncology Source Type: research

Comment on: “Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study”
(Source: Targeted Oncology)
Source: Targeted Oncology - May 27, 2020 Category: Cancer & Oncology Source Type: research

MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside
AbstractNon-coding RNAs represent a significant proportion of the human genome. After having been considered as ‘junk’ for a long time, non-coding RNAs are now well established as playing important roles in maintaining cellular homeostasis and functions. Some non-coding RNAs show cell- and tissue-specific expression patterns and are specifically deregulated under pathological conditions (e.g. cancer). Therefore, non-coding RNAs have been extensively studied as potential biomarkers in the context of different diseases with a focus on microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) for several years. Since ...
Source: Targeted Oncology - May 25, 2020 Category: Cancer & Oncology Source Type: research

Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors
AbstractBackgroundImmune checkpoint inhibitors (ICIs) demonstrated improved overall survival (OS) in heavily pretreated unselected patients with metastatic gastro-esophageal junction (mGOJ)/gastric cancer (GC). Attempts to select patients based on programmed death-ligand 1 (PD-L1) expression appear to be suboptimal. A strong rationale suggests a prognostic role for inflammatory biomarkers for ICI-treated patients with mGOJ/GC.ObjectiveOur objective was to assess whether inflammatory markers are associated with survival in ICI-treated patients with mGOJ/GC.MethodsTen inflammatory markers were retrospectively analyzed at bas...
Source: Targeted Oncology - May 24, 2020 Category: Cancer & Oncology Source Type: research

Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review
ConclusionsThe uptake of EGFR mutation testing of patients with NSCLC is suboptimal in many parts of the world. Incomplete uptake of testing is fuelled by selective testing referral practices, sample limitations, and funding constraints. (Source: Targeted Oncology)
Source: Targeted Oncology - May 22, 2020 Category: Cancer & Oncology Source Type: research

Impact of the COVID-19 Outbreak on the Management of Patients with Cancer
AbstractThe coronavirus SARS-CoV-2 (COVID-19) outbreak is having a profound impact on the management of patients with cancer. In this review, we comprehensively investigate the various aspects of cancer care during the pandemic, taking advantage of data generated in Asia and Europe at the frontline of the COVID-19 pandemic spread. Cancer wards have been subjected to several modifications to protect patients and healthcare professionals from COVID-19 infection, while attempting to maintain cancer diagnosis, therapy, and research. In this setting, the management of COVID-19 infected patients with cancer is particularly chall...
Source: Targeted Oncology - May 22, 2020 Category: Cancer & Oncology Source Type: research

Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations
AbstractBackgroundEpidermal growth factor receptor (EGFR) exon 19 deletions (19dels) appear in a large number of variants, which has not been distinguished in previously published trials despite differences in deletion and insertion locations.ObjectiveThe aim of this study was to investigate the therapeutic response of patients with differentEGFR exon 19dels to first-generation tyrosine kinase inhibitors (TKIs) and the mechanisms by which their tumors acquire resistance to these TKIs.Patients and MethodsThe clinical outcomes of 195 patients harboringEGFR exon 19dels and receiving first-generation EGFR TKIs between July 201...
Source: Targeted Oncology - May 16, 2020 Category: Cancer & Oncology Source Type: research

Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy
ConclusionsThis study demonstrates that the NLR is an independent prognostic factor in patients with gastric or gastroesophageal junction cancer treated with nivolumab monotherapy. Careful attention must be paid when nivolumab monotherapy is used to treat patients with gastric cancer with a NLR  >  2.5. (Source: Targeted Oncology)
Source: Targeted Oncology - April 21, 2020 Category: Cancer & Oncology Source Type: research

Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond
AbstractAcute myeloid leukemia (AML) is a disease of the hematopoietic system that remains a therapeutic challenge despite advances in our understanding of the underlying cancer biology over the past decade. Recent developments in molecular targeting have shown promising results in treating leukemia, paving the way for novel treatment strategies. The discovery of drugs that promote apoptosis in leukemic cells has translated to encouraging activity in clinical trials. B-cell lymphoma (BCL)-2 inhibition has been at the center of drug development efforts to target apoptosis in AML. Remarkable clinical success with venetoclax ...
Source: Targeted Oncology - April 21, 2020 Category: Cancer & Oncology Source Type: research

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
ConclusionsDespite sound rationale and demonstrable pharmacodynamic tumor activity in relevant tumor populations, a dose and schedule could not be identified for this drug combination that was both tolerable and offered clear efficacy in the population assessed.Clinicaltrials.gov identifierNCT01392521. (Source: Targeted Oncology)
Source: Targeted Oncology - April 20, 2020 Category: Cancer & Oncology Source Type: research

Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients
AbstractBackgroundA taxane plus ramucirumab as second-line therapy followed by a checkpoint inhibitor (CPI) in third line has become a standard treatment strategy for advanced gastric cancer.ObjectiveHerein, we investigated the impact of prior ramucirumab use on the efficacy of third-line immunotherapy and performed an exploratory analysis to identify potential biomarkers for the success of immunotherapy.Patients and MethodsWe retrospectively analyzed patients receiving CPI as a third-line treatment for advanced gastric cancer between January 2015 and March 2019. Clinicopathologic data, including patient characteristics, h...
Source: Targeted Oncology - April 20, 2020 Category: Cancer & Oncology Source Type: research

Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer
ConclusionsThe overall activity or number of NK cells may be a useful biomarker to predict immunotherapy response in patients with NSCLC. (Source: Targeted Oncology)
Source: Targeted Oncology - April 13, 2020 Category: Cancer & Oncology Source Type: research

Genomic Alterations and MYD88 MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib
In this study, tissue samples from DLBCL patients (n = 212) were retrospectively collected and sequenced by target-capturing panels of either 413 or 112 genes that are frequently mutated in non-Hodgkin’s lymphoma. Sixty patients withMYD88 mutations and available clinical information were included for further analysis.ResultsSevenMYD88MUT variants were identified, L265P (65.0%,n = 39), S219C (13.3%,n = 8), S243N (8.3%,n = 5), P258L (6.7%,n = 4), F283V (1.7%,n = 1), P141R (1.7%,n = 1), and V217F (1.7%,n = 1)....
Source: Targeted Oncology - April 1, 2020 Category: Cancer & Oncology Source Type: research

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
ConclusionsWe conclude that oral AZA when combined with CDZ achieves successful tumor regression in both CDX and PDX models. Furthermore, the combination of AZA  + CDZ with VEN in a PDX model emulated responses seen with VEN + AZA in the clinic, implying a potential all-oral VEN-based therapy opportunity in myeloid diseases. (Source: Targeted Oncology)
Source: Targeted Oncology - March 28, 2020 Category: Cancer & Oncology Source Type: research

Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma
ConclusionsSpecific MDSC subsets correlate with NLR. Higher WB UNC-MDSC levels and higher NLR were negative prognostic factors. Given the feasibility of serial blood draws, dynamic assessment of MDSC over time and further validation with longer follow-up are warranted. (Source: Targeted Oncology)
Source: Targeted Oncology - March 23, 2020 Category: Cancer & Oncology Source Type: research

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study
ConclusionsCombined treatment with gefitinib plus pemetrexed resulted in improved OS over gefitinib alone. A synergistic inhibitory effect between gefitinib and pemetrexed was observed on lung adenocarcinoma cell growth. Gene expression profile analysis revealed potential signaling pathways, including AKT signaling, contributing to the synergism.Clinical trial registration numberNCT02148380. (Source: Targeted Oncology)
Source: Targeted Oncology - March 13, 2020 Category: Cancer & Oncology Source Type: research

Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study
ConclusionGefitinib demonstrated modest anti-tumor activity and a manageable safety profile in chemotherapy-refractory solid tumors with EGFR amplification or sensitivity to an EGFR inhibitor identified through a drug-screening platform with PDCs.ClinicalTrials.gov identifierNCT02447419. (Source: Targeted Oncology)
Source: Targeted Oncology - February 27, 2020 Category: Cancer & Oncology Source Type: research

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
ConclusionsLorlatinib showed substantial intracranial activity in patients with pretreated ALK-positive NSCLC, with or without baseline CNS metastases, whose disease progressed on crizotinib or second-generation ALK TKIs.ClinicalTrials.gov identifierNCT01970865. (Source: Targeted Oncology)
Source: Targeted Oncology - February 14, 2020 Category: Cancer & Oncology Source Type: research

Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer
ConclusionsHigh TMB was associated with a better outcome in advanced NSCLC patients who received PD-1/PD-L1 inhibitors in China. Further studies are needed to confirm our findings. (Source: Targeted Oncology)
Source: Targeted Oncology - February 12, 2020 Category: Cancer & Oncology Source Type: research

Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice
ConclusionsPatients treated with aflibercept in real-world clinical practice achieved similar survival outcomes as those treated within randomised trials. Cumulative survival data provide a benchmark for future studies and enable indirect comparisons with other treatment sequences used in mCRC. (Source: Targeted Oncology)
Source: Targeted Oncology - February 12, 2020 Category: Cancer & Oncology Source Type: research

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study
ConclusionsAdavosertib 175  mg bid for 2.5 days was chosen as the recommended Phase II dose in combination with paclitaxel and carboplatin in Asian patients. (Source: Targeted Oncology)
Source: Targeted Oncology - February 7, 2020 Category: Cancer & Oncology Source Type: research

c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis
Conclusionsc-MET could play a role in the resistance to everolimus and its inhibition should be evaluated in breast cancer. (Source: Targeted Oncology)
Source: Targeted Oncology - February 4, 2020 Category: Cancer & Oncology Source Type: research

Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study
The objective of the ALICE-2 study is to define a prognostic angiogenesis profile to better identify HCC patients who are more likely to benefit from sorafenib treatment.Patients and methodsFrom 2008 to 2015, all consecutive HCC patients receiving sorafenib according to the Italian label were tested for specificHIF-1 α,VEGF, andVEGFR SNPs. Results from angiogenesis genotyping were then correlated with clinical outcome parameters.ResultsGlobally, a total of 210 patients were enrolled. At multivariate analysis rs12434438 ofHIF1 α, rs2010963 ofVEGF-A, and rs4604006 ofVEGF-C were confirmed as independent predictive...
Source: Targeted Oncology - February 4, 2020 Category: Cancer & Oncology Source Type: research

American Society of Hematology (ASH) 61st Annual Meeting: Orlando, FL, USA, 6 –10 December 2019
(Source: Targeted Oncology)
Source: Targeted Oncology - January 29, 2020 Category: Cancer & Oncology Source Type: research

Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy
ConclusionsPathogenic mutations identified by gene panel sequencing have potential predictive value for targeted therapy of melanoma and are worth further validation in a larger series of cases. The role of some known mutations (e.g.CDK4R24,PTEN c.801  + 1G >  A,CTNNB1S45F) as well as variants of unknown significance identified in this study (e.g.MITFR316K,KITG498S) in the generation of resistance to BRAF/MEK inhibitors should be further investigated. (Source: Targeted Oncology)
Source: Targeted Oncology - January 25, 2020 Category: Cancer & Oncology Source Type: research

2019 San Antonio Breast Cancer Symposium: San Antonio, TX, USA, 10 –14 December 2019
(Source: Targeted Oncology)
Source: Targeted Oncology - January 25, 2020 Category: Cancer & Oncology Source Type: research

Association Between Glutathione- S -Transferase Gene Polymorphisms and Responses to Tyrosine Kinase Inhibitor Treatment in Patients with Chronic Myeloid Leukemia: A Meta-analysis
This study aimed to review and meta-analyze treatment responses to TKIs in patients with CML andGST gene polymorphisms, includingGSTT1,GSTM1, andGSTP1.Patients and MethodsWe searched four medical databases, PubMed, Web of Science, the Cochrane Library, and Embase, by using keywords related toGST gene polymorphisms and clinical responses in CML patients receiving TKI treatment. The meta-analysis was performed using RevMan version 5.3 and Comprehensive Meta-Analysis software version 3.0. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to examine the association betweenGSTT1,GSTM1, andGSTP1 polymorphisms ...
Source: Targeted Oncology - January 23, 2020 Category: Cancer & Oncology Source Type: research

BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis
ConclusionsNegative BRCA1 expression assessed by immunohistochemistry was associated with a better prognosis in epithelial ovarian cancer. (Source: Targeted Oncology)
Source: Targeted Oncology - January 20, 2020 Category: Cancer & Oncology Source Type: research

Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review
AbstractThe immunotherapy revolution in cancer treatment involves a variety of specialists, not only oncologists, but also internal medicine physicians, endocrinologists, dermatologists, gastroenterologists, rheumatologists, and radiologists, introducing new scenarios and novel challenges in the diagnosis and management of a number of novel immune-related adverse events. Among these, immune checkpoint inhibitor-induced pancreatic injury has been described (occurring in up to 4% of patients) and has been reported to be responsible for visits to the emergency departments in up to 1.9% of patients treated with immune checkpoi...
Source: Targeted Oncology - January 11, 2020 Category: Cancer & Oncology Source Type: research

Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study
ConclusionThis phase II trial using pemetrexed/erlotinib in metastatic CRC with high EGFR expression met the primary endpoint of tumor response.Trial RegistrationThis study was registered at ClinicalTrials.gov (number NCT03086538). (Source: Targeted Oncology)
Source: Targeted Oncology - December 9, 2019 Category: Cancer & Oncology Source Type: research

Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
ConclusionsFOLFIRI  + S has signs of clinical activity in patients with advanced gastric and GEJ adenocarcinoma, and the side-effect profile was similar to previously reported studies. Current treatment paradigms in gastric cancer probably negate further study of this regimen.ClinicalTrials.gov identifier: NCT00524186. (Source: Targeted Oncology)
Source: Targeted Oncology - December 4, 2019 Category: Cancer & Oncology Source Type: research

Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond
AbstractImmune checkpoints inhibitors (ICIs) have been a breakthrough, with unique response and survival patterns compared with chemotherapy for patients with advanced Mismatch Repair-deficient/Microsatellite instable (dMMR/MSI) colorectal cancer, but have shown disappointing results in Mismatch Repair-proficient/Microsatellite stable (pMMR/MSS) colorectal cancer. As up to 50% of patients harboring dMMR/MSI advanced cancers will ultimately progress after PD-1 blockade, biomarkers are needed to predict response/resistance to immunotherapy and to select patients for immunomodulating combination therapies. Patients with pMMR/...
Source: Targeted Oncology - November 30, 2019 Category: Cancer & Oncology Source Type: research

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study
ConclusionsAnalyses adjusting for treatment switching using two different statistical approaches confirm the improved survival benefit of adding AA  + P to ADT in patients with newly diagnosed mCSPC.Trial RegistrationClinicalTrials.gov identifier NCT01715285. (Source: Targeted Oncology)
Source: Targeted Oncology - November 21, 2019 Category: Cancer & Oncology Source Type: research

Treatment Sequencing and Clinical Outcomes in BRAF -Positive and BRAF -Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice
ConclusionsInBRAF mutated patients with normal LDH, first-line immunotherapy seems a more effective approach. We have demonstrated that althoughBRAF mutation is a negative prognostic factor in stage IV melanoma, the use of two different systemic treatment modalities allows achievement of comparable survival inBRAF mutated andBRAF wild-type patients. (Source: Targeted Oncology)
Source: Targeted Oncology - November 21, 2019 Category: Cancer & Oncology Source Type: research

High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities
ConclusionsSmall sub-sets of breast cancers with high TMB exist and may present an opportunity for effective immunotherapeutic targeting. (Source: Targeted Oncology)
Source: Targeted Oncology - November 18, 2019 Category: Cancer & Oncology Source Type: research

Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
AbstractAtezolizumab (Tecentriq®), a humanized, anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody, in combination with bevacizumab, carboplatin and paclitaxel (ABCP) or with carboplatin and nab-paclitaxel (ACnP) has been approved as first-line treatment for metastatic nonsquamous NSCLC, based on results from the randomized IMpower150 and IMpower130 studies in chemotherapy-na ïve patients with nonsquamous metastatic NSCLC. In IMpower150, ABCP prolonged progression-free survival (PFS) and overall survival (OS) relative to BCP, regardless ofEGFR orALK status, liver metastases at baseline or PD-L1 expres...
Source: Targeted Oncology - November 14, 2019 Category: Cancer & Oncology Source Type: research

Acknowledgement to Referees
(Source: Targeted Oncology)
Source: Targeted Oncology - November 11, 2019 Category: Cancer & Oncology Source Type: research

Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
ConclusionsWe developed a ddPCR assay to quantify the T790M mutation in plasma. Quantification of longitudinal plasma T790M mutation may allow noninvasive assessment of drug resistance and guide follow-up treatment in TKI-treated patients with NSCLC.Trial RegistrationClinical Trials.gov identifier: NCT02804100. (Source: Targeted Oncology)
Source: Targeted Oncology - November 6, 2019 Category: Cancer & Oncology Source Type: research

Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
AbstractA subcutaneous (SC) formulation of trastuzumab, a potent humanized anti-Human Epidermal growth factor Receptor 2 (HER2) receptor monoclonal antibody, with a recombinant hyaluronidase (Herceptin Hylecta ™; Herceptin®) is indicated in the USA and EU for the treatment of HER2-positive breast cancer. In the phase III pivotal HannaH trial, SC trastuzumab was noninferior to the standard intravenous (IV) formulation of trastuzumab with respect to trough drug concentrations and pathological complete response in patients with HER2-positive early breast cancer. Other clinical outcomes, including event-free survival...
Source: Targeted Oncology - November 4, 2019 Category: Cancer & Oncology Source Type: research

Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab
ConclusionsRamucirumab-induced hypertension was not associated with improved OS and PFS in patients with mCRC treated with ramucirumab and FOLFIRI, but severe diarrhea was associated with poorer OS and PFS.Clinical trial registrationNo. NCT01183780. (Source: Targeted Oncology)
Source: Targeted Oncology - November 1, 2019 Category: Cancer & Oncology Source Type: research

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study
AbstractBackgroundEvidence on PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) therapy for advanced non-small-cell lung cancer (NSCLC) is mainly based on clinical trials in first- or second-line settings.ObjectiveWe aimed to investigate response and prognostic factors with special regard to third- or later-line therapy.Patients and MethodsWe retrospectively analyzed all patients who had received ICI monotherapy with nivolumab, pembrolizumab, or atezolizumab for advanced NSCLC. Computed tomography evaluations were analyzed using response evaluation criteria in solid tumors (RECIST, version 1.1). Kaplan –Meier ana...
Source: Targeted Oncology - October 25, 2019 Category: Cancer & Oncology Source Type: research

PARP Inhibition in Cancer: An Update on Clinical Development
AbstractPARP (poly(ADP-ribose) polymerase) inhibitors represent a novel class of anti-cancer therapy; they take advantage of synthetic lethality and induce cell death by exploiting a defect in DNA repair. This class of medication was initially evaluated in patients with BRCA-associated tumors, but efficacy was also demonstrated in other populations. Since 2014, four PARP inhibitors have been approved in various indications: olaparib, niraparib, and rucaparib in high-grade serous ovarian cancer, and olaparib and talazoparib in metastatic breast cancer. The exact indications and study populations vary slightly between the di...
Source: Targeted Oncology - October 17, 2019 Category: Cancer & Oncology Source Type: research

Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study
ConclusionsBevacizumab was the only prescribed targeted therapy in first-line treatment. Considering the limited number of patients receiving first-line bevacizumab and the unknown reasons to prescribe additional targeted therapy, the corresponding survival rates of patients treated with and without additional bevacizumab in first-line treatment might suggest a limited clinical effect of bevacizumab in addition to first-line palliative chemotherapy on OS. Future research should focus on identifying the subgroup of patients who might benefit OR benefiting from anti-VEGF therapy in metastatic SBA. (Source: Targeted Oncology)
Source: Targeted Oncology - October 17, 2019 Category: Cancer & Oncology Source Type: research

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
AbstractABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. ABP 980 is approved in the United States, European Union, and Japan for all the indications of trastuzumab, based on the totality of evidence (TOE) gathered by the systematic step-wise accumulation of comparative analytical, preclinical, and clinical (pharmacokinetics [PK], efficacy, safety and immunogenicity) data for ABP  980 and trastuzumab...
Source: Targeted Oncology - October 16, 2019 Category: Cancer & Oncology Source Type: research

First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options
AbstractUntil recently, a dichotomy existed in the front-line approach of metastatic clear-cell renal cell carcinoma (mRCC). Specifically, patients received either targeted therapy or immunotherapy. Targeted therapy entailed use of agents blocking signaling through the vascular endothelial growth factor (VEGF) receptor, such as cabozantinib, sunitinib, or pazopanib. Immunotherapy entailed dual therapy with nivolumab and ipilimumab, both checkpoint inhibitors for intermediate/poor International Metastatic RCC Database Consortium (IMDC)-risk disease patients. Within the past year, two datasets have emerged that led to recent...
Source: Targeted Oncology - October 8, 2019 Category: Cancer & Oncology Source Type: research

Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials
AbstractThe clinical development of cancer drugs is rapidly moving from empirical “one drug fits all” or development-by-tumor-type approaches towards more personalized treatment models. A deeper understanding of cancer and the immune system, novel technologies, and powerful analytics have fueled an increase in precision oncology approaches integrating the molecular profiles o f the tumor with the clinical profile of the patient. While this approach has been successful for targeted therapies, the complex mode of action of immunotherapies will likely require integration of clinical profiling with more comprehensi...
Source: Targeted Oncology - October 8, 2019 Category: Cancer & Oncology Source Type: research

Correction to: Combination Treatment with an Antibody –Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer
The article Combination Treatment with an Antibody –Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer, written by Y. Louise Wan, Puja Sapra, James Bolton, Jia Xin Chua, Lindy G. Durrant and Peter L. Stern, was originally published under a CC BY-NC 4.0 license , but has now been made available under a CC BY 4.0 license. (Source: Targeted Oncology)
Source: Targeted Oncology - October 3, 2019 Category: Cancer & Oncology Source Type: research

Evaluation of Clinically Relevant Drug –Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
ConclusionsThese analyses suggest the pharmacokinetic profile of darolutamide is not affected by a number of commonly administered drugs in patients with nmCRPC. Although pharmacokinetic data have indicated that darolutamide has the potential to interact with rosuvastatin, used to assess DDI in these studies, this finding did not seem to translate into increased AEs due to statin use in the ARAMIS trial.Clinicaltrials.gov identifier: NCT02200614. (Source: Targeted Oncology)
Source: Targeted Oncology - September 30, 2019 Category: Cancer & Oncology Source Type: research

Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study
This study included 68 patients treated at Asan Medical Center (Seoul, Republic of Korea) between 2014 and 2016 with metastatic or unresectable CRC refractory to standard therapies. Regorafenib (160  mg/day on days 1–21 followed by a 7-day break) was administered.ResultsThe median patient age was 58 (range 26 –72) years; 61.8% of patients were male. Among the 68 patients, 50 (73.5%) showed hypothyroidism; 39 (57.4%) had subclinical and 11 (16.2%) had symptomatic hypothyroidism. Overall, the objective response rate (ORR) and disease control rate (DCR) were 7.4% and 70.6%, respectively; both were signifi can...
Source: Targeted Oncology - September 25, 2019 Category: Cancer & Oncology Source Type: research

Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia
AbstractVenetoclax (Venclyxto®; Venclexta®) is a first-in-class, oral, selective B cell lymphoma-2 (BCL-2) inhibitor. The drug is approved in numerous countries, including those of the EU and in the USA, for the treatment of adults with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL); the specific indication(s) for venetoclax may vary between individual countries. Venetoclax monotherapy or combination therapy with rituximab was an effective treatment, provided durable responses, and had a manageable safety profile in pivotal clinical trials in adults with RR CLL, including in patients with adverse pr...
Source: Targeted Oncology - September 21, 2019 Category: Cancer & Oncology Source Type: research